In FY23, the Group Scientific Advisory Committee comprising of the Scientific Directors from across Australia and Asia have focused on providing our patients with market-leading success rates through our commitment to scientific excellence, the trialling and application of new technologies, as well as innovation via the translation of research outcomes to clinical practice.
Key highlights of achievements undertaken in FY23 include:
- Being awarded the Medical Research Future Fund Mitochondrial Donation grant ($15 million) in partnership with Monash University and Murdoch Children’s Research Institute to deliver a pilot clinical trial and notably to establish Australia’s first and only mitochondrial donation program.
- The successful completion of three research studies investigating PIEZO microinjection technology that demonstrate improved patient outcomes, followed by the subsequent clinical rollout of PIEZO technology across our laboratory network, making Monash IVF Group the first Australian IVF provider offering this technology.
- Greater expansion of Embryoscope+ timelapse technology across Monash IVF Group, with 11 incubators now installed across the country. In addition, the introduction of single step medium across numerous sites, maximising the utility of the Embryoscopes, reducing embryo handling and therefore reducing the risk associated with the culture systems.
- Facilitating the recruitment of patients for a nationwide multi-centre clinical trial in partnership with Memphasys (ASX: MEM) and the University of Newcastle to investigate the efficacy of a novel sperm separation device (FELIX) to improve fertilisation results and embryo quality and viability.
- Publication of 38 peer-reviewed studies in leading fertility journals and the presentation of numerous research award-winning abstracts and invited talks at international and national forums by Monash IVF Group clinical and science teams.